Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tumour-cell-vaccine-GVAX

Drug Profile

Tumour-cell-vaccine-GVAX

Alternative Names: CG-1940/CG-8711; CG-8123; GVAX Leukemia; GVAX Pancreas; GVAX Prostate; STINGVAX™

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cell Genesys
  • Developer Aduro BioTech; ANI Pharmaceuticals; BioSante Pharmaceuticals; Cell Genesys; Dana-Farber Cancer Institute; Eli Lilly; Hussman Foundation; Merck Sharp & Dohme; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Cancer vaccines; Gene therapies; Tumour cell vaccines
  • Mechanism of Action Gene transference; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Malignant melanoma; Acute myeloid leukaemia; Chronic myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Pancreatic cancer
  • Phase I/II Prostate cancer
  • No development reported Breast cancer; Cancer; Chronic myeloid leukaemia; Malignant melanoma; Multiple myeloma
  • Discontinued Non-small cell lung cancer; Renal cancer

Most Recent Events

  • 01 Jul 2018 Phase-I clinical trials in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (Intradermal) (NCT03153410)
  • 23 Jan 2018 Sidney Kimmel Comprehensive Cancer Center initiates enrolment in a phase II trial for Pancreatic cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (NCT03006302)
  • 01 Dec 2017 Sidney Kimmel Comprehensive Cancer Center, Aduro Biotech, and Bristol-Myers Squibb initiates enrolment in a phase II trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (NCT03190265)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top